We are live on ! Find out more

Intensity Therapeutics

INTS

Market cap $10.8M

3.28 USD

+0.19

6.15%

At close Updated Nov 11, 4:00 PM EST

1 day

6.15%

5 days

3.8%

1 month

-0.91%

3 months

-21.9%

6 months

-34.4%

Year to date

-67.78%

1 year

-66.36%

5 years

-97.8%

10 years

-97.8%

About: Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Employees: 7

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. ( INTS ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Joseph Talamo - Chief Financial Officer Conference Call Participants Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Charles Wallace - H.C. Wainwright & Co, LLC, Research Division Ilya Zubkov - Freedom Broker, Research Division James Molloy - Alliance Global Partners, Research Division Conversation Operator Good morning, and welcome to the Intensity Therapeutics Third Quarter 2026 Financial Results Conference Call.

Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript

Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resumed in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study in the third quarter of 2026 Cash and cash equivalents of $8.5 million as of September 30, 2026 Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.

Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate update SHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the third quarter ended September 30, 2026, before the market opens on November 5, 2026.

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invasive breast cancer cells were detected in the axillary lymph nodes in 6 of the 7 INT230-6 patients after INT230-6 treatment, despite 5 (71%) of the patients were initially biopsy-proven node-positive SHELTON, Conn., Oct. 23, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announced data for the first seven patients in Cohort A in the INVINCIBLE-4 Study will be presented in an ePoster by The Swiss Cancer Institute, the Company's collaborator in the INVINCIBLE-4 Study, at the ESMO 2026 Virtual Congress Platform beginning on Friday, 23 October at 08:00 CEST.

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that it will participate in the H.C.

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate update SHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026.

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in Switzerland.

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile Strengthened balance sheet supporting disciplined clinical development strategy SHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provides a mid-year update highlighting the Company's late-stage development programs and growing strategic partnering focus for INT230-6.

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

See News Rankings

Price charts implemented using Lightweight Charts™